bims-hemali Biomed News
on Hematologic malignancies
Issue of 2026–08–02
29 papers selected by
Alexandros Alexandropoulos, Γενικό Νοσοκομείο Αθηνών Λαϊκό



  1. Blood. 2026 Jul 28. pii: blood.2026033565. [Epub ahead of print]
      Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
    DOI:  https://doi.org/10.1182/blood.2026033565
  2. Clin Lymphoma Myeloma Leuk. 2026 Jun 30. pii: S2152-2650(26)00203-X. [Epub ahead of print]
      Waldenström macroglobulinemia (WM) or Immunoglobulin M (IgM) lymphoplasmacytic lymphoma is a heterogeneous clinicopathologic entity with distinguishing features that include circulating monoclonal IgM, lymphoplasmacytic marrow infiltrate, and in > 90% of patients, a recurrent clonal mutation, MYD88L265. The clinical manifestations are highly variable. Symptomatic patients with indication(s) to start therapy are initially managed with either fixed-duration chemoimmunotherapy (for example, bendamustine-rituximab) or a covalent Bruton tyrosine kinase (BTK) inhibitor (for example, zanubrutinib) given until progression or intolerable toxicity, although these 2 highly different approaches have not been directly compared in randomized trials. MYD88L265P, CXCR4, and TP53 mutational status may potentially impact treatment decision-making. Options for managing WM are expanding as several recent trials demonstrate the promising efficacy of BCL-2 inhibitors, noncovalent BTK inhibitors and BTK degraders in patients that are previously exposed, or refractory, to a covalent BTK inhibitor and/or chemoimmunotherapy. Preliminary data with novel approaches involving CAR-T cell and bispecific antibodies are continuing to be generated, and the reports, thus far, are encouraging.
    Keywords:  BCL2-inhibitors; BTK inhibitors; Chemoimmunotherapy; IgM monoclonal gammopathy; Lymphoplasmacytic lymphoma
    DOI:  https://doi.org/10.1016/j.clml.2026.06.016
  3. Blood. 2026 Jul 28. pii: blood.2026034611. [Epub ahead of print]
      Azacitidine (Aza) plus venetoclax (Ven) is standard treatment for older/unfit patients with newly diagnosed (ND) acute myeloid leukemia (AML). The approved 28-day (D) Ven schedule is associated with prolonged cytopenias, causing frequent dose reductions and cycle delays. Retrospective studies show similar efficacy and reduced toxicity with abbreviated Ven dosing, but prospective data is lacking. We conducted OPTI-AML(NCT03013998), a prospective randomized phase 2 trial comparing 28D Ven (AV28) versus 14D (AV14) with Aza (75mg/m²x7D) for C1-2 in genomically agnostic ND-AML patients ≥60 years. The primary endpoint was complete remission (CR) rate achieved at any time with two cycles of therapy. Between 2023-2025, 169 patients received AV28 (n=83) or AV14 (n=86). CR across two cycles was 49.4% (AV28) versus 43% (AV14); difference of 6.4% [90%CI:-6.1% to 19.0%], not meeting non-inferiority criteria. Patients with NPM1/ IDH2 mutations had higher CR rates with AV28 (60.9% vs. 33.3%), while CR rates were equivalent (45%) for other subgroups. Composite CR rates were 80.7% (AV28) versus 68.6% (AV14) and MRD negativity was similar (77.6% vs. 76.5%). Although AV28 had more frequent treatment interruptions, count recovery after C2, grade ≥3 adverse events and early mortality were similar. In conclusion, the study did not demonstrate non-inferiority of AV14 compared with AV28 during C1-2 in an unselected ND-AML cohort. However, as the confidence interval for the difference covered 0, CR rate for AV28 was not significantly different than AV14. Certain subgroups may benefit from prolonged Ven exposure, but these findings require validation in larger studies, especially as triplet regimens evolve.
    DOI:  https://doi.org/10.1182/blood.2026034611
  4. Clin Lymphoma Myeloma Leuk. 2026 Jul 08. pii: S2152-2650(26)00206-5. [Epub ahead of print]
      Dasatinib 100 mg once daily is effective for chronic-phase chronic myeloid leukemia (CP-CML), but dose-related toxicity may limit long-term tolerability. We therefore evaluated whether dasatinib 50 mg once daily as an initial dose strategy preserves efficacy while improving safety compared with 100 mg once daily. We performed a systematic review and meta-analysis of adults with CP-CML treated with initial dasatinib 50 mg once daily. MEDLINE via PubMed, Embase, Cochrane CENTRAL, and Web of Science were searched from inception to March 15, 2026. Direct comparative studies of dasatinib 50 mg versus 100 mg were included in the primary analysis; whereas single-arm 50 mg cohorts were summarized as supportive evidence. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Among 613 records identified, 10 reports met eligibility criteria and 7 nonoverlapping analytic reports were retained. Two studies directly compared frontline dasatinib 50 mg versus 100 mg. Twelve-month major molecular response was similar between doses (RR 1.07, 95% CI, 0.92-1.24), while complete cytogenetic response favored 50 mg in unadjusted analysis (RR 1.09, 95% CI, 1.02-1.16). Dasatinib 50 mg reduced pleural effusion (RR 0.20, 95% CI, 0.08-0.50) and thrombocytopenia (RR 0.71, 95% CI, 0.52-0.96). Supportive frontline single-arm data showed pooled 12-month MMR and CCyR proportions of 70.6% and 95.0%, respectively.Overall, initial dasatinib 50 mg once daily may preserve key efficacy outcomes while improving tolerability in CP-CML. Prospective controlled studies are needed.
    Keywords:  Chronic-phase CML; Low-dose dasatinib; Molecular response; Pleural effusion; Treatment tolerability
    DOI:  https://doi.org/10.1016/j.clml.2026.07.001
  5. Blood Adv. 2026 Jul 31. pii: bloodadvances.2026020293. [Epub ahead of print]
      Melphalan 200 mg/m² is the standard conditioning regimen for autologous hematopoietic stem cell transplantation (ASCT) in multiple myeloma, but further dose escalation is limited by toxicity. Evomela, a propylene‑glycol-free melphalan with enhanced stability, enables safer dose intensification and pharmacokinetic (PK) optimization. We conducted a prospective phase I/II trial to optimize Evomela dosing and infusion schedule in newly diagnosed myeloma patients undergoing ASCT. Primary objectives included dose/schedule optimization using a Bayesian design and PK characterization; secondary objectives included minimal residual disease (MRD)‑negative complete response (CR) at day 90, toxicity, and progression‑free survival (PFS). Sixty patients were randomized to short (30-60 mins) or long (8-9 hrs) Evomela infusions at 200 or 225 mg/m². No grade ≥4 non‑hematologic toxicities or day‑100 non‑relapse mortality occurred. MRD-negative stringent (s)CR/CR at day 90 was 45% (43% in the short infusion arm and 47% in the long infusion arm), with similar toxicity and PFS between the schedules. A higher melphalan area under the concentration-time curve (AUC) was strongly associated with MRD‑negative sCR/CR (posterior probability of benefit [PBE] = 0.99) without increased toxicity, but not with PFS. In propensity‑matched comparisons, Evomela was associated with longer PFS than melphalan 200 mg/m² (MEL200) (PBE = 0.90). These results support Evomela as a platform for safe dose intensification and AUC‑guided conditioning in newly diagnosed myeloma patients undergoing ASCT. (NCT03417284).
    DOI:  https://doi.org/10.1182/bloodadvances.2026020293
  6. Exp Hematol Oncol. 2026 Jul 27. pii: 64. [Epub ahead of print]15(1):
      Venetoclax (VEN) combined with a hypomethylating agent (HMA) has become a standard-of-care frontline therapy for unfit patients with newly diagnosed acute myeloid leukemia (ND AML). The VIALE-A trial established the clinical benefit of VEN plus azacitidine (AZA), with a composite complete remission rate (CRc) of 66.4% and a median overall survival (OS) of 14.7 months. Nevertheless, remission durability remains heterogeneous, and the regimen is non-curative for many patients. Improving remission rates and long-term survival therefore remains an urgent unmet clinical need. VEN/HMA-based triplet regimens incorporating targeted agents are emerging as promising strategies in ND AML, particularly FLT3 inhibitor-based combinations reported at the 2025 American Society of Hematology (ASH) Annual Meeting. Notably, longer-term follow-up data from a study of gilteritinib plus VEN/AZA in patients with ND FLT3-mutated AML showed a median OS of 29.7 months. Additional VEN/HMA-based strategies, including combinations with menin inhibitors and other novel agents, are also being investigated. Here, we provide an overview of the latest clinical updates on VEN/HMA-based triplet regimens in ND AML presented at the 2025 ASH Annual Meeting.
    Keywords:  Acute myeloid leukemia; Hypomethylating agents; Newly diagnosed; Triplet regimen; Venetoclax
    DOI:  https://doi.org/10.1186/s40164-026-00810-3
  7. NEJM Evid. 2026 Aug;5(8): EVIDoa2500333
       BACKGROUND: Eltrombopag is an effective second-line therapy for immune thrombocytopenia (ITP), but its long-term efficacy is limited. All-trans retinoic acid (ATRA) has immunomodulatory effects targeting ITP pathophysiology. We investigated whether combining ATRA with eltrombopag improves long-term outcomes for glucocorticoid-resistant or relapsed ITP.
    METHODS: We conducted a multicenter, randomized, open-label trial in adults with glucocorticoid-resistant or relapsed ITP (platelets <30×109/l). Patients were randomly assigned 1:1 to ATRA (12 weeks) plus eltrombopag or eltrombopag monotherapy. The primary outcome was an 18-month sustained response (platelet count ≥30×109/l without clinically significant bleeding or rescue therapy).
    RESULTS: Ninety-six patients were randomly assigned, 48 per group. At 18 months, 60% (29/48) in the ATRA-plus-eltrombopag group achieved a sustained response, versus 35% (17/48) in the monotherapy group (odds ratio: 2.78; 95% confidence interval [CI]: 1.22-6.37; P=0.014). The combination was associated with a higher complete response rate (79% vs. 58%; 95% CI for difference, 2 to 39 percentage points) and longer median response duration (75 vs. 37 weeks; hazard ratio for relapse, 0.45; 95% CI, 0.23-0.86). Adverse events were comparable between groups, with no grade 3-4 events or treatment-related deaths. However, clinically significant bleeding of World Health Organization grades 2 or 3 was 21% in the combination group at baseline compared with 10% in the monotherapy group.
    CONCLUSIONS: In patients with glucocorticoid-resistant or relapsed ITP, a 12-week ATRA course with eltrombopag significantly enhanced the 18-month sustained response rate compared to eltrombopag alone. (Funded by Capital Health Research and Development of Special Fund and others; ClinicalTrials.gov number, NCT05438875.).
    DOI:  https://doi.org/10.1056/EVIDoa2500333
  8. Blood Cancer J. 2026 Jul 25. pii: 122. [Epub ahead of print]16(1):
      Selinexor for the Treatment of Myelofibrosis. SVR35- spleen volume reduction ≥ 35%, TSS- total symptom score.
    DOI:  https://doi.org/10.1038/s41408-026-01587-8
  9. Hematol Oncol. 2026 Sep;44(5): e70230
      Ruxolitinib is first-line therapy for intermediate/high-risk myelofibrosis (MF), but ∼50% of patients discontinue within 1 year due to loss of efficacy or intolerance. Four JAK inhibitors (gecacitinib, fedratinib, pacritinib, momelotinib) are approved for ruxolitinib-pretreated MF, with no head-to-head trials comparing their efficacy and safety. This study used matching-adjusted indirect comparison (MAIC) to compare these four agents, aiming to provide evidence-based insights for treatment decision-making in ruxolitinib-resistant or intolerant MF. Individual patient data (IPD) of gecacitinib (100 mg BID; ZGJAK006/ZGJAK017, n = 78) and published data of comparators (fedratinib: JAKARTA-2/FREEDOM2; pacritinib: PAC203; momelotinib: SIMPLIFY-2/MOMENTUM) were analyzed. Eight baseline characteristics were matched. Efficacy outcomes (week-24 SVR35, TSS50, transfusion independence [TI]) were reported as odds ratios (ORs); safety as risk differences (RDs). Gecacitinib showed superior SVR35 versus fedratinib (JAKARTA-2: OR = 3.96, 95% CI = 1.37-11.39, P = 0.0108), pacritinib (PAC203: OR = 6.10, 95% CI = 1.54-24.23, P = 0.0101), and momelotinib (SIMPLIFY-2: OR = 8.65, 95% CI = 1.86-40.31, P = 0.0060), and superior TSS50 versus pacritinib (OR = 7.62 95% CI = 1.84-31.51, P = 0.0050) and momelotinib (MOMENTUM: OR = 7.52, 95% CI = 1.63-34.61, P = 0.0096). Numerically, gecacitinib had better TI. It also had significantly lower incidences of diarrhea, nausea, and AE-related treatment discontinuation. Hematologic AE profiles of gecacitinib varied by comparator cohort. Gecacitinib showed favorable efficacy and tolerability signals versus several comparators, suggesting it may be a valuable second-line option.
    Keywords:  JAK inhibitor; gecacitinib; matching‐adjusted indirect comparison (MAIC); myelofibrosis; second‐line treatment
    DOI:  https://doi.org/10.1002/hon.70230
  10. Blood Adv. 2026 Jul 27. pii: bloodadvances.2026020294. [Epub ahead of print]
      Measurable residual disease (MRD) is a powerful prognostic tool in multiple myeloma, but predictors of achieving MRD negativity after autologous stem cell transplantation (ASCT) are not well defined. We studied 814 patients who achieved at least a very good partial response after ASCT between January 2016 and January 2023 and underwent MRD assessment by next-generation flow cytometry (median sensitivity 2.4x10-6). Overall, 48% (n=387) achieved MRD negativity post-ASCT. The presence of t(11;14) (OR 2.1, 95% CI 1.4-3.2; p<0.01) and pre-transplant response less than complete remission (OR 2.1, 95% CI 1.2-3.7; p<0.01) independently predicted MRD positivity. MRD-positive patients had inferior progression-free survival (PFS) (HR 1.99, 95% CI 1.53-2.58; p<0.001) and overall survival (OS) (HR 1.62, 95% CI 1.10-2.28; p=0.009). Despite lower MRD-negative rate, 5-year PFS was similar among t(11;14) MRD-positive (58%) and MRD-negative (63%); p=0.12. The adverse prognostic effect of high-risk cytogenetics (HRCA) on 5-year PFS appears partially mitigated in MRD-negative patients, 5-year PFS was 73% in those without ≥2 HRCA compared with 55% in those with ≥2 HRCA (HR 1.9, 95% CI 1.2-3.3; p=0.01). In the MRD-positive cohort, 5-year PFS was 53% in patients without ≥2 HRCA versus 17% in those with ≥2 HRCA (HR 2.4, 95% CI 1.6-3.6; p<0.01). Additionally, higher residual clonal plasma cell burden within MRD-positive disease was associated with inferior PFS (HR 2.4, 95% CI 1.2-6.9; p=0.002). This study highlights that presence of t(11;14) independently predicts MRD positivity post-ASCT, although it does not significantly impact prognosis in this subgroup.
    DOI:  https://doi.org/10.1182/bloodadvances.2026020294
  11. Blood. 2026 Jul 29. pii: blood.2026033437. [Epub ahead of print]
      Light chain (AL) amyloidosis is a fatal plasma cell dyscrasia characterized by the overproduction of misfolded l or k immunoglobulin light chains (LCs) produced by clonal plasma cells, which aggregate into amyloid fibrils that deposit in tissues and cause progressive organ damage. While current anti-plasma cell therapies reduce the production of new amyloidogenic LCs, pre-existing fibrils persist and continue to drive organ damage. Amyloid-targeting monoclonal antibodies birtamimab and anselamimab were developed and tested for active AL amyloid clearance; however, they failed to meet the primary endpoint in Phase 3 trials, presumably due to insufficient binding affinity for l LC amyloid, which occurs in ~80% of patients. Here, we reported the development of 1F10, a novel high-affinity l subtype-specific amyloid-binding monoclonal antibody that does not cross-react with soluble native l or k LCs. 1F10 exhibits superior binding affinity to l AL amyloid fibrils and significantly enhances antibody-dependent phagocytosis (ADP) of l AL amyloid compared with birtamimab and anselamimab. Specific binding of 1F10 to l amyloid is confirmed by immunohistochemical staining of patient-derived tissue biopsies. Importantly, 1F10 demonstrates robust in vivo activity, significantly accelerating the resolution of l amyloid fibrils in an AL amyloidoma mouse model. Together, these findings establish 1F10 antibody as a promising subtype-specific immunotherapeutic candidate for targeting l LC amyloid, addressing a critical unmet need for the majority of patients with AL amyloidosis.
    DOI:  https://doi.org/10.1182/blood.2026033437
  12. Blood Adv. 2026 Jul 29. pii: bloodadvances.2026021402. [Epub ahead of print]
      Classic Hodgkin lymphoma (cHL) associated with Epstein-Barr virus (EBV) positivity as well as non-nodular sclerosis (non-NS) histologic subtypes have demonstrated poorer outcomes compared to EBV-negative and nodular sclerosis cases. We report a prespecified subset analysis of patients enrolled in the phase III SWOG S1826 trial to evaluate outcomes based on EBV status and histologic subtype in patients treated with nivolumab-AVD (N-AVD) or brentuximab vedotin (BV)-AVD. In the phase III SWOG S1826 trial, patients with stage III-IV cHL were randomized to N-AVD or BV-AVD. Of 970 eligible patients, 522 had known EBV status. N-AVD improved 3-year progression-free survival (PFS) in EBV-positive (91% v 70%; HR, 0.30; P = 0.01) and EBV-negative patients (90% v 84%; HR, 0.64; P = 0.09). Among 664 patients with slides available for histology review, 102 (15.4%) had non-NS subtypes. N-AVD prolonged 3-year PFS in patients with non-NS (86% v 63%; HR, 0.33; P = 0.006) and NS histologic subtype (93% v 86%; HR, 0.53; P = 0.01). Non-NS histology independently was associated with inferior outcomes (HR, 2.54; P < 0.0001) after adjusting for treatment in the entire cohort. However, N-AVD treatment still had favorable PFS within this high-risk group. In addition, patients with EBV positivity or non-NS histology cHL treated with BV-AVD had significantly worse PFS (HR, 1.97; P = 0.03 for EBV; and HR, 3.08; P < 0.0001 for histology). N-AVD substantially abrogated the historically poor prognosis associated with EBV positivity and non-NS histology in advanced-stage cHL. These results support N-AVD as frontline standard of care, particularly in high-risk biologic subgroups. (NCT03907488).
    DOI:  https://doi.org/10.1182/bloodadvances.2026021402
  13. Trends Cancer. 2026 Jul 28. pii: S2405-8033(26)00157-3. [Epub ahead of print]
      Frontline treatments for mantle cell lymphoma were historically dictated by age and fitness for intensive chemoimmunotherapy and autologous stem cell transplantation. While yielding high response rates, these approaches are associated with treatment-related morbidity and disease relapse. The therapeutic landscape is trending toward biological precision. This review highlights the timely frontline integration of novel targeted agents that directly challenge the need for traditional consolidative transplants while de-escalating or even sparing chemotherapy. Measurable residual disease is increasingly used to identify early relapses and inform the duration and individualization of therapy. By integrating targeted and immune-engaging therapeutics with optimized maintenance to deepen responses and prolong survival, these advancements aim to maximize long-term remission while minimizing toxicity.
    Keywords:  BTK inhibitors; MRD; frontline therapy; mantle cell lymphoma; targeted therapy; treatment de-escalation
    DOI:  https://doi.org/10.1016/j.trecan.2026.07.001
  14. Curr Oncol Rep. 2026 Jul 30. pii: 77. [Epub ahead of print]28(1):
       PURPOSE OF REVIEW: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, characterized by a relapsing and remitting course and a median overall survival exceeding 15-20 years with modern therapy. While chemoimmunotherapy remains the cornerstone of frontline management, the rapid approval of novel agents, including bispecific antibodies, CAR T-cell products, and antibody-drug conjugates, has fundamentally reshaped the relapsed/refractory (R/R) landscape. This review summarizes current evidence across the treatment continuum and propose a practical, risk-adapted sequencing framework.
    RECENT FINDINGS: Bispecific antibodies (mosunetuzumab, epcoritamab) have demonstrated durable complete responses in heavily pretreated FL, with manageable toxicity profiles. CAR T-cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel) are approved in R/R FL after two or more prior lines, offering high response rates albeit notable logistal and safety considerations. Frontline trials incorporating lenalidomide-rituximab have established chemotherapy-free option with long-term outcomes comparable to chemoimmunotherapy. Emerging data on antibody-drug conjugates and bispecific antibody combination therapy continue to expand the therapeutic arsenal. Despite favorable long-term outcomes for many patients with FL, relapse remains common and remission typically shortens with successive lines of therapy. The growing number of effective agents with distinct mechanisms of action creates both opportunity and complexity. Evidence-based sequencing strategies that account for prior therapy exposure, patient fitness and mechanism-specific considerations are increasingly critical to maximizing outcomes across the disease trajectory.
    Keywords:  Bispecific Antibodies; CAR T-cell therapy; Follicular Lymphoma; Indolent Lymphoma
    DOI:  https://doi.org/10.1007/s11912-026-01803-5
  15. Nat Rev Clin Oncol. 2026 Jul 29.
      De-escalation of therapy constitutes a new phase in the development of therapeutic approaches for patients with multiple myeloma (MM) and is aimed at maintaining durable disease control while reducing the toxicity and burden associated with prolonged treatment. Given that increasingly effective agents, including immunotherapies, are now used earlier in the course of MM, we must assess not only how much therapy is needed to enable a clinical response but also how much is required to sustain it. In this Review, we synthesize emerging evidence supporting multiple de-escalation strategies, including dose and schedule modification, withdrawal of individual agents from multidrug regimens, fixed-duration approaches with treatment-free intervals, minimal residual disease-adapted strategies, omission of autologous stem cell transplantation and single infusion of chimeric antigen receptor T cells. We highlight how contemporary trials are beginning to define the patient populations and treatment components most amenable to de-escalation while exposing ongoing uncertainties and challenges, including those relating to monitoring strategies, re-treatment criteria and feasibility. Finally, we discuss methodological and implementation challenges including end point selection, clinical trial design, integration of correlative translational research, funding models and the involvement of key stakeholders required to translate de-escalation approaches from concept to a clinical trial and, eventually, routine clinical practice.
    DOI:  https://doi.org/10.1038/s41571-026-01186-3
  16. Eur J Haematol. 2026 Jul 30.
      Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle. Best overall response rate was 76% and did not differ significantly between schedules (p = 0.38). Median overall survival (OS) was numerically longer with 7d (28.4 months) than with 14d (11.4 months) or > 14d (6.7 months), although unadjusted differences were not significant (p = 0.23). At cycle level, the 7d schedule was associated with fewer infections and more complication-free cycles than both longer schedules, while bleeding events were similar. Grade 4 cytopenias and platelet transfusion requirements were also lower with 7d. In an adjusted Cox model, prior HMA exposure, non-favourable ELN 2024 risk and age ≥ 75 years were associated with inferior OS, whereas the 7d schedule remained associated with improved OS versus > 14d (HR 0.33, p = 0.03). Higher recent grade 4 neutropenia burden was independently associated with inferior OS. These findings suggest that abbreviated VEN exposure may improve tolerability without clear loss of efficacy in AML patients ineligible for intensive chemotherapy.
    Keywords:  acute myeloid leukaemia; dose‐adjusted treatment; hypomethylating agents; venetoclax
    DOI:  https://doi.org/10.1111/ejh.70279
  17. Blood. 2026 Jul 29. pii: blood.2026033241. [Epub ahead of print]
      The c-MYC (MYC) oncogene is a critical driver of multiple myeloma (MM), however, direct targeting of the MYC protein has proven challenging due to its intrinsic structural disorder. In this study, we evaluated the biological activity and molecular mechanism of a ribonuclease-targeting chimera (RiboTAC) designed to promote the degradation of MYC mRNA (MYC-RiboTAC) across a panel of primary patient MM samples and MM cell lines. This heterobifunctional molecule consists of a small molecule targeting the MYC internal ribosomal entry site (IRES) conjugated to a small-molecule recruiter of endogenous RNaseL. The MYC-RiboTAC reduces MYC mRNA and protein levels in an RNase L-dependent manner, selectively inhibits MYC-driven transcriptional programs, and exhibits potent anti-MM activity. It effectively suppresses cell growth in MM cells co-expressing MYC and RNase L, even in the presence of the protective bone marrow. Furthermore, it synergizes with clinically active agents such as carfilzomib, lenalidomide, and pomalidomide. Importantly, MYC-RiboTAC displays favorable safety and pharmacokinetic profiles in mice and significantly suppresses tumor growth in NOD SCID mice bearing MM xenografts, as shown in two different models. These findings highlight the potential of RNA degraders to target mRNAs encoding "undruggable" proteins such as MYC, offering a promising avenue for precision cancer therapy.
    DOI:  https://doi.org/10.1182/blood.2026033241
  18. Curr Oncol. 2026 Jul 17. pii: 426. [Epub ahead of print]33(7):
      First-line (1L) therapy for mantle cell lymphoma (MCL) continues to evolve rapidly, with several recent phase II and phase III trials consistently showing the activity of novel covalent Bruton's tyrosine kinase inhibitor (cBTKi) combinations. Historical treatment selection criteria such as patient age, fitness, and eligibility for autologous stem cell transplantation generally remain applicable for some, but not all, of these novel regimens. This potential for flexibility necessitates the consideration of additional factors during decision-making, such as MCL biology, patient risk tolerance, logistical and resource implications, and the impact on use of later-line options. This paper presents three illustrative patient cases to explore 1L therapy selection among these new and emerging cBTKi options. The realized and anticipated benefits, limitations, and challenges and persisting evidence gaps associated with these regimens are discussed.
    Keywords:  B-cell lymphoma 2; Bruton’s tyrosine kinase inhibitor; acalabrutinib; chemotherapy-free; ibrutinib; mantle cell lymphoma; zanubrutinib
    DOI:  https://doi.org/10.3390/curroncol33070426
  19. Leuk Lymphoma. 2026 Jul 26. 1-8
      Preclinical data support myeloid cell leukemia 1 (MCL1) inhibition in the treatment of acute myeloid leukemia (AML). Patients with relapsed/refractory myelodysplastic syndrome (n = 1) or AML (n = 32) or older patients with untreated AML ineligible to receive intensive chemotherapy (n = 5) were treated in this phase 1 study of S64315, an MCL1 inhibitor (NCT02979366). Seven dose levels (50, 100, 200, 250, 300, 400, and 500 mg) were tested. The most common toxicities were nausea and vomiting, diarrhea, and increased transaminases and troponin levels. Seven patients experienced dose-limiting toxicities (DLTs), including increased cardiac biomarkers (n = 3), grade 3 increased transaminases with hyperbilirubinemia (n = 2), and decreased cardiac ejection (n = 1). Three DLTs occurred at the 500-mg dose, which was intolerable; a maximum tolerated dose was not determined since fewer than six patients were treated at doses between 100 and 400 mg. Exposure to S64315 increased in a dose-dependent manner between 50 and 500 mg. There were no objective responses to therapy.
    Keywords:  Myeloid leukemias and dysplasia; cell cycle and apoptosis changes; pharmacotherapeutics
    DOI:  https://doi.org/10.1080/10428194.2026.2699287
  20. Curr Oncol. 2026 Jul 12. pii: 419. [Epub ahead of print]33(7):
      The prognostic significance of myelodysplasia-related gene mutations (MDS-RGMs), defined by the ELN 2022 classification and Mutation-Enhanced International Prognostic Score System high-risk mutations (MIPSS70-HRM), in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs) remains unclear. We conducted a retrospective study of 101 AP/BP MPN patients with intermediate-risk cytogenetics, excluding TP53 mutations and adverse-risk karyotypes. We evaluated whether MDS-RGM or MIPSS70-HRM predicted treatment response, overall survival (OS), or disease-free survival (DFS) and whether treatment intensity affected OS. Patients included AP (29.7%) and BP (70.3%), with 55% receiving intensive therapy. Allogeneic stem cell transplant (ASCT) significantly improved OS (HR 0.31, 95% CI 0.19-0.50; p < 0.0001), as did AP versus BP at transformation (HR: 0.43, 95% CI 0.26-0.73; p = 0.0016). Among patients ≤ 70 years with ECOG 0-1 (N = 77), ASCT and reversion to chronic-phase MPN (cMPN) were associated with longer OS (p < 0.0001 and p = 0.0475). Treatment intensity alone did not significantly affect OS (p = 0.1991).
    Keywords:  high-risk mutations; myeloproliferative neoplasm; treatment intensity
    DOI:  https://doi.org/10.3390/curroncol33070419
  21. Future Oncol. 2026 Aug;22(18): 2201-2211
       BACKGROUND: Given the rarity of marginal zone lymphoma (MZL), real-world data on relapsed/refractory (R/R) MZL are limited.
    METHODS: This retrospective panel-based chart review study examined patient characteristics and treatment patterns among patients with R/R MZL who received a second or third line (2L or 3L) of therapy between 1 January 2014 and 31 December 2021 in 7 countries. Treatment patterns were summarized overall and by MZL type.
    RESULTS: The study included 526 patients, 513 with 2L and 13 with 3L as index treatment. The median age of 2L patients was 67.0 years. Most patients had stage III or IV disease and intermediate or high-risk prognostic scores. Around 60.0% of the patients had nodal, 22.8% had splenic, and 14.2% had mucosa-associated lymphoid tissue (MALT) MZL. Most patients received chemoimmunotherapy (42.8%), Bruton's tyrosine kinase inhibitors (BTKi; 25.1%), or lenalidomide and rituximab/obinutuzumab (16.3%) in 2L. Treatment patterns varied across subtypes, with notable differences in 2L BTKi use.
    CONCLUSIONS: These findings suggest variability and limitations in the treatment selection for R/R MZL beyond frontline therapy, with the choice of treatment mostly limited to chemoimmunotherapy and BTKi. This study provides much-needed real-world evidence that can help guide clinical management and the development of novel therapies.
    Keywords:  Relapsed/refractory; marginal zone lymphoma; panel-based chart review; retrospective; treatment patterns
    DOI:  https://doi.org/10.1080/14796694.2026.2700479
  22. bioRxiv. 2026 Jul 13. pii: 2026.07.10.737821. [Epub ahead of print]
      Targeting oxidative phosphorylation (OXPHOS) represents an attractive therapeutic strategy in acute myeloid leukemia, which exhibits exceptional dependence on mitochondrial respiration compared to normal hematopoietic cells. However, clinical attempts to exploit this vulnerability have been limited by on-target toxicity to healthy tissue. Here, we comprehensively compare the cellular consequences of inhibiting distinct nodes of the electron transport chain in AML. We demonstrate that selective inhibition of the F 1 subunit of ATP synthase with EB2023 (ammocidin A) delivers an energetic stress to AML cells without the profound redox stress that characterizes complex I inhibition, preventing NAD⁺/NADH imbalance and allowing continued TCA cycling. Further, the duration of OXPHOS inhibition is transient in nature in vivo , a finding revealed through pharmacokinetic and serial pharmacodynamic monitoring of AMPK phosphorylation accompanied by OPA1-mediated mitochondrial structural remodeling that primes AML cells for BCL2 inhibitor synergy. EB2023 in combination with venetoclax demonstrates potent anti-AML activity across cell lines and patient-derived xenograft models at doses that spare normal hematopoietic progenitors and avoid the neuropathy and sustained detrimental systemic metabolic rewiring in healthy tissues associated with prior efforts to target OXPHOS. These findings establish F 1 -selective ATP synthase inhibition as a clinically actionable therapeutic strategy in AML and establish the duration of OXPHOS inhibition as a critical and previously underappreciated determinant of therapeutic index.
    DOI:  https://doi.org/10.64898/2026.07.10.737821
  23. J Cell Mol Med. 2026 Aug;30(15): e71296
      The tumour microenvironment (TME) of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients is associated with resistance of DLBCL cells to CD19 CAR-T cells. How to improve TME in DLBCL and improve the efficacy of CAR-T cell therapy remains to be further explored. We observed the sensitivity of HBL-1/U2932 cells pretreated with BTK inhibitors (BTKi) to CAR-T cells with flow cytometry (FCM). The effect of pretreatment of BTKi on the polarisation state of alternative activated M2 macrophages was observed with FCM, real-time PCR and Western blot method. The effect of Notch1 agonist on expressions of Arg-1 protein, iNOS protein, Notch1 protein and RBP-J protein in alternative activated M2 macrophages was observed by Western blot method. Then the expression consistency of Notch-1 and RBP-J in activated M2 macrophages was observed by siRNA transfection of Notch-1. The cytotoxicity of CD19 CAR-T cells on HBL-1/U2932 cells pretreated with ibrutinib/orelabrutinib was higher than that of HBL-1/U2932 cells unpretreated with ibrutinib/orelabrutinib. Cytotoxicity of CAR-T cells to HBL-1 cells in coculture system with alternative activated M2 macrophages was very low. This drug resistance could be reversed by replacing the M2 macrophages (M2 macrophages after 48 h pretreatment with BTKi) in coculture system. Pretreatment with BTKi could down-regulate the expression of CD206 and IL-10 in activated M2 macrophages. And pretreatment with BTKi down-regulated the expression of Arg-1 and upregulated the expression of iNOS in activated M2 macrophages. The upregulation polarisation of M2 macrophages by Notch1 agonist could be reversed by BTKi. Expression of RBP-J protein decreased in alternative activated M2 macrophages by siRNA silencing Notch 1. Pretreatment with BTKi could down-regulate the polarisation of M2 macrophages and reverse the resistance of DLBCL cells which were cocultured with alternative activated M2 macrophages to CAR-T cells. This effect might be achieved by downregulating the Notch-RBP-J pathway.
    Keywords:  Bruton's tyrosine kinase inhibitor; chimeric antigen receptor; diffuse large B‐cell lymphoma cells; macrophages
    DOI:  https://doi.org/10.1111/jcmm.71296
  24. Cancer Med. 2026 Aug;15(8): e72147
      The incidence of primary central nervous system low-grade B-cell lymphoma (PCNSL-LG) is rare. We aimed to provide the first large-scale analysis of treatment modalities, survival trends, and prognostic factors for PCNSL-LG. Patient data diagnosed between 2000 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 267 adult PCNSL-LG patients were included. The year of diagnosis was divided into the time period-1 (2000-2009) and the time period-2 (2010-2021). Radiotherapy alone usage remained stable over time (27.34% vs. 30.22%, p = 0.605). Chemotherapy alone showed a modest, non-significant increase (25.00% vs. 31.66%, p = 0.229), while combined chemoradiotherapy declined significantly from 29.69% to 15.11% (p = 0.004). The 1-, 5-, and 10-year overall survival (OS) rates for all PCNSL-LG patients were 84.3%, 73.4%, and 61.8%, respectively. Overall survival improved significantly, with median OS extending from 11.25 years in period-1 to not reached in period-2 (HR 0.46, 95% CI: 0.28-0.74; p = 0.001). Surgery was associated with improved outcomes compared with non-surgical management (HR 0.47, 95% CI: 0.31-0.72, p < 0.001). In patients with MALT lymphoma histology, no significant prognostic difference was observed across treatment modalities (p = 0.838). This study underscores a marked improvement in survival among PCNSL-LG patients over the past two decades and offers valuable insights for optimizing clinical management and improving patient outcomes.
    Keywords:  PCNSL; SEER; low‐grade B‐cell lymphoma; prognostic factors; survival outcomes
    DOI:  https://doi.org/10.1002/cam4.72147
  25. Drug Des Devel Ther. 2026 ;20 568214
      The selective inhibition of Bruton's tyrosine kinase (BTK) has emerged as a promising therapeutic strategy for autoimmune diseases by targeting key signaling pathways in both adaptive and innate immune cells. Initially developed for B cell malignancies, BTK inhibitors are now being evaluated across a range of immune-mediated disorders, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Beyond B cell receptor signaling, BTK inhibition modulates Fc receptor- and toll-like receptor-dependent activation of myeloid cells, thereby extending its therapeutic relevance. BTK inhibitors comprise a pharmacologically diverse class, including covalent (irreversible) and non-covalent (reversible) inhibitors, which differ in binding mode, selectivity, and pharmacokinetic properties. These differences are increasingly recognized as critical determinants of clinical performance. While early studies demonstrated robust target engagement and anti-inflammatory activity, clinical outcomes have been inconsistent across diseases. In multiple sclerosis, BTK inhibitors have shown promising effects on inflammatory activity and emerging signals on disability progression. In contrast, in rheumatoid arthritis and systemic lupus erythematosus, several compounds failed to meet primary clinical endpoints despite clear pharmacodynamic effects. These divergent outcomes highlight that the efficacy of BTK inhibition depends on disease-specific immune architecture and the relative contribution of BTK-dependent pathways. Safety considerations, including hepatotoxicity signals observed in late-stage trials, and differences between individual compounds further complicate clinical development. In this review, we summarize the mechanistic rationale of BTK inhibition, compare key pharmacological properties across BTK inhibitors, and critically assess clinical trial outcomes. We further discuss key challenges, including patient heterogeneity, trial design constraints, the lack of direct comparative studies, and outline future directions such as biomarker-driven patient selection and the development of BTK degraders.
    Keywords:  BTK inhibition; PROTACs; autoimmune diseases; molecular glue degraders; multiple sclerosis; rheumatoid arthritis; systemic lupus erythematosus
    DOI:  https://doi.org/10.2147/DDDT.S568214
  26. Cancers (Basel). 2026 Jul 08. pii: 2184. [Epub ahead of print]18(14):
      Background/Objectives: Multiple myeloma (MM) is a complex hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. [18F]FDG PET/CT has emerged as a key imaging modality, demonstrating high sensitivity and specificity for the detection of metabolically active disease compared with conventional imaging techniques. This review examines the role of PET/CT imaging in evaluating therapeutic response in symptomatic myeloma, including minimal residual disease (MRD) assessment. Methods: We surveyed the literature published between 2014 and 2024 across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed articles evaluating PET imaging in the assessment of treatment response in multiple myeloma. Results: [18F]FDG PET/CT provides a whole-body assessment of disease burden, extramedullary involvement detection, and early metabolic response evaluation. Standardized response assessment criteria (Deauville, IMPeTUs, IMWG) have enhanced the reproducibility and accuracy of treatment monitoring. Semiquantitative parameters including SUVmax and metabolic tumor volume (MTV) provide useful prognostic information with PET negativity correlating with improved progression-free and overall survival. The integration of PET/CT with bone marrow assessment techniques (next-generation flow cytometry and sequencing) optimizes MRD evaluation and patient stratification. Conclusions: PET/CT represents a valuable imaging tool for improving therapeutic decision making and risk stratification in MM management. Emerging radiotracers beyond FDG, including [11C]choline, [11C]methionine, and targeted agents like [68Ga]pentixafor and CD38-targeted immunoPET tracers, hold promise for enhanced diagnostic capabilities in specific clinical contexts.
    Keywords:  PET/CT; minimal residual disease; molecular imaging; multiple myeloma; novel radiotracers; prognostic factors; response criteria; therapy monitoring
    DOI:  https://doi.org/10.3390/cancers18142184